For Authors

What we publish

• Original Research — studies reporting new data from clinic or laboratory work.
• Safety and Data Reports — adverse-event and safety data, with the mandatory adverse-event table described below.
• Protocol Papers — formulations and administration protocols, with the mandatory formulation table described below.
• Systematic and Narrative Reviews — evidence reviews that translate published studies for practicing clinicians; systematic reviews follow PRISMA.
• Case Reports — a single case or small series, with written patient consent.
• Editorials, Commentary and Letters — argument and response, by invitation or approval of a proposal.

Every research and review manuscript carries a structured abstract, keywords, a discussion that includes a limitations paragraph, and statements covering conflicts of interest, funding, data availability, and ethics. References use numbered Vancouver style, and a claim in the text must be traceable to a numbered reference or to data presented in the paper itself. Marketing material, vendor white papers, and testimonials are not acceptable sources for clinical claims.

Reporting standards for IV therapy

Any paper describing an infusion must include a formulation table stating, for each ingredient: the ingredient and its form, dose, concentration, diluent and final volume, the final calculated osmolarity where a mixture is described, infusion rate and duration, and the compounding source identified by type — 503A pharmacy, 503B outsourcing facility, or manufacturer product — with beyond-use dating practice stated. Papers that cannot state a final osmolarity for a multi-ingredient mixture must say why, and must not describe the mixture as within physiologic range.

Patient selection must be stated: inclusion and exclusion criteria, screening labs where relevant, contraindications, and stopping rules.

Adverse events and the denominator rule

Adverse events are reported by type and severity on the journal’s CTCAE-adapted grading scale, Grades 1 to 5. Events of Grade 3 or higher are described individually, including management and outcome.

Every safety paper reports a denominator — total infusions and total patients — and rates per 1,000 infusions by event type and grade. A paper that reports events without a denominator will be returned before review.

Ethics and reporting checklists

• Ethics approval — human-subjects research names the IRB or ethics body that approved it, or the body that granted a written exemption or waiver. A claim that approval was not required, without a written determination, is not acceptable.
• Consent — case reports require written patient consent, held by the authors and confirmed at submission; retrospective reviews state the basis for any waiver and the de-identification method used.
• Checklists — CONSORT for trials, STROBE for observational studies, PRISMA for systematic reviews, CARE for case reports.
• Trial registration — trials are registered in a public registry before enrollment, with the registration number printed in the abstract.

Authorship and AI disclosure

Authorship follows the four ICMJE criteria: substantial contribution; drafting or critical revision; final approval; and accountability. Contributors who do not meet all four are named in the acknowledgments. Gift, guest, and ghost authorship are prohibited.

Any use of artificial intelligence tools in drafting, analysis, or image creation must be disclosed in the methods or acknowledgments. AI tools cannot be authors, and authors remain fully responsible for the content. Submissions must be original, not under consideration elsewhere, and the journal follows COPE guidance on publication misconduct.

Full author guidelines will be published when submissions open.